Head-to-head comparison
Amble vs VyrarX
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Telehealth weight loss provider offering compounded semaglutide and tiered tirzepatide programs.
From $179/mo (lowest dose rung) sema · From $289/mo (lowest dose rung) tirz · Verified July 2026
Marked down on: Limited public information on program details
Desk Score
VyrarX is a LegitScript-certified telehealth platform offering compounded semaglutide (from $179/month) and compounded tirzepatide (from $329/month) via weekly injection, with provider messaging and nutrition coaching included — and no ladder published behind either "from".
From $179/mo sema · From $329/mo tirz · Verified August 2026
Marked down on: Both prices are "from" figures with nothing behind them — no ladder, no dose banding, no plan lengths — on a site whose own badge reads "Transparent pricing"
VyrarX takes this head-to-head with the higher Desk Score, 78/100 (C+) against 76/100 (C) for Amble. Amble still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Amble
76/100
C
VyrarX
78/100
C+
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Amble | VyrarX |
|---|---|---|
| Semaglutide | From $179/molowest dose rung$179/mo (starting dose, compounded) | From $179/moFrom $179/mo (compounded; the site publishes no ladder, dose banding or term behind the word "from") |
| Tirzepatide | From $289/molowest dose rung$289/mo (starting dose, compounded) | From $329/moFrom $329/mo (compounded; the site publishes no ladder, dose banding or term behind the word "from") |
| Coverage | All 50 states | 47 states (not California, South Carolina or New Jersey) |
| Brand-name | Compounded only | Compounded only |
| Oral option | Injectable only | Injectable only |
| Best for | Mainstream telehealth GLP-1 access. | Readers outside California, South Carolina and New Jersey who want provider messaging and nutrition coaching bundled in, and will complete a five-minute intake to learn what the price becomes at their dose. |
| Desk Score | 76/100C | 78/100C+ |
The verdict
Desk pick — VyrarXVyrarX takes this head-to-head with the higher Desk Score, 78/100 (C+) against 76/100 (C) for Amble. Amble still holds its ground where its strengths line up with yours.
Choose Amble if…
Mainstream telehealth GLP-1 access.
From $179/mo (lowest dose rung) sema · From $289/mo (lowest dose rung) tirz · All 50 states
Choose VyrarX if…
Readers outside California, South Carolina and New Jersey who want provider messaging and nutrition coaching bundled in, and will complete a five-minute intake to learn what the price becomes at their dose.
From $179/mo sema · From $329/mo tirz · 47 states (not California, South Carolina or New Jersey)
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: Amble · VyrarX.
Also here
CoreAge Rx leads the whole ranking at 94/100
Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
More head-to-heads
- Amble vs CoreAge Rx
- CoreAge Rx vs VyrarX
- Amble vs Ondra Health
- Trimi vs VyrarX
- Amble vs Trimi
- HealthRX vs VyrarX
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.